Jacobio Pharmaceuticals Says Cash Runway Extends at Least Four Years

MT Newswires Live
05/19

Jacobio Pharmaceuticals (HKG:1167) said its cash runway extends at least four years, supported by about 2.10 billion yuan in cash and bank balances, capital-protected structured deposits, and available bank credit facilities, according to a Tuesday Hong Kong bourse filing.

The drug company said it has repurchased 747,800 shares for about HK$34.2 million as of May 18.

Jacobio also received a $100 million upfront payment from AstraZeneca under a strategic collaboration agreement, along with 8.6 million yuan in sales royalty payments from Allist for the June-to-December 2025 period, the filing said.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10